An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Alpha-1 Antitrypsin Deficiency (AATD)
  • Age: Between 18 - 70 Years
  • Gender: Male or Female

Inclusion Criteria

AATD diagnosis, willing to undergo 2 bronchoscopies

Non-smoker

Willing to hold current AATD treatment until study ends (about 5 months).

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176